PharmaRen is a startup chemistry-based pharmaceutical company in St. Louis, Missouri. Our focus is the design, synthesis and manufacturing of:
complex synthetic molecules for the injectable cytotoxic generic market.
We are also developing a class of innovative, heparin-like drug candidates with the potential of effective treatments for cancers and central nervous system diseases.
At PharmaRen, we use a proprietary discovery platform to bring our products to market. We have a stellar team in place, and plan to deliver our first anti-cancer drug to the market in near future. The research, development and pilot scale-up of the intermediates have been completed, and the cGMP manufacturing of the validation batches are planned for 2024. Our pipeline include high potency injectables of high values and low volumes. These includes complex synthetic API for generic market. We are particularly interested in the triple negative breast cancer, heparinic anticoagulants and glycoproteine biosimilar.
On the discovery side:
PharmaRen (PharmaRen Discovery LLC) has just completed the first phase of its 2nd generation synthetic non-anticoagulant heparin-like molecules. These heparinoids are “single” molecules designed for evaluation as drug candidates where the extracellular matrix’s heparan sulfate plays a crucial role in the physiological and disease processes. An account of developments and commercial availability of these new and innovative molecules will be disclosed soon, though some are available and could be accessed through www.heparinbuildingblocks.com.
If you want learn more about us, contact us using this form.
Ixabepilone is an approved chemotherapeutic agent for the treatment of metastatic breast cancer. Although it targets microtubules similarly to docetaxel and paclitaxel, ixabepilone has activity in patients that are refractory to taxanes.
Please Get Latest Public Health Information From CDC:
Get the Latest Research from NIH:
www.nih.gov